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Using recombinant proteins as standards, we calculated the amount of Vpr and Vpx present in HIV-2ROD particles. We
find 2000–3000 copies of Vpx per particle but only 40–50 copies of Vpr. We investigated the reasons for this discrepancy
between Vpx and Vpr and found that viral factors, including HIV-2 Vpx, do not restrict its incorporation. Instead, the accumula-
tion of HIV-2ROD Vpr during infection is restricted by a short protein half-life which acts to limit its virion incorporation. The
half-life of HIV-2 Vpr was calculated to be about 90 min, while HIV-2 Vpx and HIV-1 Vpr had half-lifes of 36 and 20 hr,
respectively. Moreover, while both HIV-1 Vpr and HIV-2 Vpr cause cells to accumulate in G2 of the cell cycle, the effect of
HIV-2 Vpr is attenuated relative to HIV-1 Vpr. Thus, protein stability correlates with both the function of Vpr and its virion
incorporation. q 1996 Academic Press, Inc.
INTRODUCTION complex into the nucleus of the nonproliferating cell (Em-
erman et al., 1994; Heinzinger et al., 1994). This may be
A feature which distinguishes complex retroviruses a result of Vpr’s karyophilic properties (Heinzinger et al.,
from archetypical retroviruses is the additional genetic 1994; Lu et al., 1993). De novo expression of Vpr within
information complex retroviruses require for efficient rep- different cell types has potent effects on the proliferation
lication (Cullen, 1991). The human immunodeficiency vi- and physiology of these cells (Levy et al., 1993; Mustafa
ruses encode at least six auxiliary genes, besides the and Robinson, 1993; Rogel et al., 1995). Cells which ex-
gag, pol, and env reading frames. Two of the immunodefi- press Vpr accumulate in the G2 phase of the cell cycle
ciency virus auxiliary genes, vpr and vpx, code for pro- and stop dividing (He et al., 1995; Jowett et al., 1995; Re
teins which are efficiently incorporated into virion parti- et al., 1995; Rogel et al., 1995). As a result, propagation
cles. HIV-1 encodes only Vpr; while HIV-2 and many of HIV-1 in transformed T-cell lines ultimately selects
strains of the simian immunodeficiency virus (SIV) also for cells harboring proviruses which contain premature
encode Vpx. In addition to being a virion protein, Vpr terminations of the vpr open reading frame (Rogel et al.,
displays some amino acid homology with Vpx (Tristem 1995).
et al., 1990). This has led to the speculation that both Analogous to Vpr of HIV-1, Vpx of HIV-2 is incorporated
genes are evolutionarily related and may have resulted into virus particles through an interaction with the car-
from a duplication of a single progenitor gene (Tristem boxyl-terminal region of HIV-2 Gag (Wu et al., 1994). This
et al., 1992, 1990). interaction is both specific, as Vpx will not trans-incorpo-
Vpr of HIV-1 is incorporated into virion particles rate into the HIV-1 particle (Wu et al., 1994), and efficient,
through an interaction with the carboxyl-terminal, p6 do- given the equimolar amount of Vpx and Gag in virion
main of Gag (Kondo et al., 1995; Lu et al., 1993; Paxton particles (Henderson et al., 1988; Wu et al., 1994). Vpx is
et al., 1993). Because it is present in the virion particle, also necessary for efficient infection of primary lympho-
it has been suggested Vpr acts early in infection. Genetic cytes and tissue macrophages (Gibbs et al., 1994; Guy-
analyses have demonstrated that Vpr is important for the ader et al., 1989; Kappes et al., 1991; Kawamura et al.,
infection of macrophages (Balliet et al., 1994; Connor et 1994; Park and Sodroski, 1995; Yu et al., 1991). We have
al., 1995; Emerman et al., 1994; Heinzinger et al., 1994; recently shown Vpx to be associated with the mature
Westervelt et al., 1992). We have suggested this occurs cores of HIV-2 and, thus, may be present in the viral
by Vpr-mediated translocation of the viral preintegration preintegration complex (KewalRamani and Emerman,
1996).
The function of HIV-2 Vpr is less well understood.1 To whom correspondence and reprint requests should be ad-
While Vpr from SIV are incorporated into virion particlesdressed at Room C2-023, Division of Molecular Medicine, Fred Hutchin-
(Gibbs et al., 1995; Yu et al., 1990), cell culture infectionson Cancer Research Center, 1124 Columbia St., Seattle, WA 98104.
Fax: (206) 667-6523. E-mail: memerman@fred.fhcrc.org. with HIV-2, or SIV mutated in vpr has given no clear
3260042-6822/96 $18.00
Copyright q 1996 by Academic Press, Inc.
All rights of reproduction in any form reserved.
AID VY 7838 / 6a14$$$261 03-13-96 23:50:50 vira AP: Virology
327HIV-2 VPR AND VPX
indication of the role of this gene in vitro (Dedera et al., tion site within vpr. These clones are referred to as pHIV-
2vpr and pHIV-2vpx/r, respectively, and express no de-1989; Gibbs et al., 1994; Hattori et al., 1990; Park and
Sodroski, 1995). In vivo infection of adult rhesus monkeys tectable Vpr in mammalian cell culture. The vpr mutation
in these constructs does not overlap with other openwith SIVmac mutated in vpr suggests no requirement for
Vpr in the ultimate pathogenic potential of the virus when reading frames.
The HIV-2ROD9 Gag eukaryotic expression construct,compared to wild-type SIVmac (Gibbs et al., 1995); al-
though, the progression of disease in primates infected pHIV2GagPro, contains the entire 5* HIV-2 long terminal
repeat (LTR) promoter/enhancer sequences extendingwith SIVmac mutated in vpr may be attenuated (Gibbs et
al., 1995; Hoch et al., 1995; Lang et al., 1993). Moreover, through the gag/pol open reading frames up to nucleo-
tide 3216 within pol. Nucleotide 3216 is downstream ofalthough the Vpr of SIVmac also affects the cell cycle, this
effect is much less than that of HIV-1 Vpr (Di Marzio et pro and 278 bases into the RT coding region. This vector
utilizes a human hepatitis B virus polyadenylation signalal., 1995).
HIV-2ROD contains open vpr and vpx reading frames sequence downstream of the gag/pro reading frames,
contains a simian virus 40 (SV40) origin of replication,(Guyader et al., 1989). To study the roles of HIV-2 Vpr
and Vpx during infection, the relative virion content of and requires either HIV-1 or HIV-2 Tat protein for gene
expression in eukaryotic cells. We have previously dem-both proteins was assessed. Here we find that HIV-2
Vpr, in contrast to HIV-1 Vpr and HIV-2 Vpx, is poorly onstrated that the hepatitis B virus polyadenylation signal
sequence confers Rev-independence to HIV messagesincorporated into the virion. HIV-2 Vpr is detected at
levels 60-fold reduced to HIV-2 Vpx. Although HIV-2 (Emerman et al., 1989).
Eukaryotic expression constructs derived for transientVpx incorporates into the virion particle in the same
manner as HIV-1 Vpr, Vpx does not competitively ex- expression of HIV-1 vpr, HIV-2 vpr, and HIV-2 vpx are
pLAIvpr, pRODvpR, and pRODvpX, respectively. Expres-clude specific incorporation of HIV-2 Vpr into the virion.
The limited amounts of Vpr in the HIV-2 particle corre- sion construct pLAIvpr utilizes the HIV-1LAI LTR promoter/
enhancer driving HIV-1LAI vpr followed by the SV40 poly-spond with low intracellular levels of Vpr. These cellu-
lar levels reflect an accelerated protein of half-life HIV- adenylation signal sequence. Expression construct
pRODvpR utilizes the HIV-1LAI LTR promoter/enhancer2ROD Vpr (90 min) relative to HIV-2 Vpx (36 hr) or HIV-
1 Vpr (20 hr). In addition, we find that the reduced half- driving HIV-2ROD vpr followed by the SV40 polyadenylation
signal sequence. Expression construct pRODvpX utilizeslife of HIV-2 Vpr relative to HIV-1 Vpr correlates with a
reduced effect on the cell cycle. HIV-2 Vpx, on the other the HIV-2ROD LTR promoter/enhancer driving HIV-2ROD vpx
followed by the human hepatitis B virus polyadenylationhand, has no effect on the cell cycle despite the fact
that it has a long half-life. Together, these data demon- signal sequence. Exogenous Tat was supplied by the
eukaryotic expression construct pCMVTat in these ex-strate that the cell cycle effect of Vpr has been con-
served between HIV-1 Vpr and HIV-2 Vpr, but that pro- periments for efficient expression from the HIV LTRs.
tein stability modulates the function of HIV-2 Vpr.
Recombinant proteins
MATERIALS AND METHODS
HIV-2 Vpr and Vpx were expressed as C-terminal fu-
DNA constructs
sions to maltose binding protein, MBP-Vpr or MBP-Vpx,
respectively, in an Escherichia coli strain, (CAG629,The vpr and vpx genes of HIV-2ROD9 were each ampli-
fied by the polymerase chain reaction (PCR) using prim- NEB), deficient in MBP and proteases. Free Vpr was
eluted from MBP-Vpr bound to the MBP affinity substrateers that introduced restriction sites and subsequently gel
purified, digested, and cloned into the pMAL-c bacterial amylose through precise proteolytic cleavage of the
MBP-Vpr fusion junction with human factor Xa, releasingexpression construct (New England Biolabs, NEB) for
inducible cytoplasmic expression of maltose binding pro- the unbound Vpr from the bound MBP moiety. The eluate
was further purified by negative chromatography withtein (MBP) fusions. The insertions created precise, in-
frame fusions between the upstream MBP open reading fresh amylose after which it was concentrated and exam-
ined for purity (Fig. 1). Fifty percent of the total protein inframe and the downstream vpr or vpx reading frames,
designated pCP-1 and pMBP-Vpx, respectively. The in- this fraction was judged to be cleaved Vpr by densitomet-
ric analysis.tegrity of the molecular cloning as well as the PCR ampli-
fication of the genes was verified by DNA sequencing. After purification of MBP-Vpx on amylose resin, the
fusion protein was eluted from the column with free malt-The wild-type (pROD9) and vpx-mutated HIV-2ROD
(pROD9vpx2) proviral constructs have been described ose. The purified MBP-Vpx fusion was subsequently
cleaved with factor Xa. This cleaved mixture was loadedpreviously (Guyader et al., 1989) and are referred to in the
text as pHIV-2 and pHIV-2vpx. A premature termination on to an Orange A Dyematrix affinity column (Amicon)
which binds Vpx with high avidity (KewalRamani and Em-codon was introduced into vpr of both of these proviral
constructs by Klenow-mediated fill-in of a HindIII restric- erman, 1996). After removing free MBP through washing,
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Vpx was eluted with increasing concentrations of KCl. In order to detect bound secondary antibody, blots
were reacted with SuperSignal enhanced chemilumines-The protein eluate was then concentrated and desalted
through spin filtration. This concentrate was judged to cent HRP substrates obtained from Pierce (Rockford, IL).
These reagents provided greater linearity in lumines-be greater than 95% pure (Fig. 1). Examination of 1 mg
Vpx on a silver-stained polyacrylamide gel confirmed its cence in response to increasing concentrations of target
protein. Kodak BioMax MR imaging film was exposedhigh degree of purity. Both purified recombinant stocks
were analyzed for protein concentration by the Bradford – to chemiluminescing blots for less than 3 sec before
development in quantitative assays. For densitometricLowry method (Bio-Rad).
analyses, film exposures were digitized on a flatbed
Antibodies transparency scanner, and band intensities were ana-
lyzed using ImageQuant (Molecular Dynamics).
Polyclonal antisera directed against HIV-2 Vpr was
Cell culture, transfections, and virus stocksgenerated in a New Zealand White rabbit. One milli-
gram of purified MBP-Vpr fusion protein was cleaved Human 293T cells were cultured in Dulbecco’s modi-
to completion overnight at 47C with Factor Xa and the fied Eagle’s medium (DMEM) supplemented with 10%
digestion products were resolved the next day by so- fetal bovine serum (FBS). CEMx174 cells were propa-
dium dodecyl sulfate (SDS) – polyacrylamide gel elec- gated in RPMI 1640 medium supplemented with 10% FBS
trophoresis (PAGE). Resolved digestion products were and 0.3 g/liter L-glutamine.
visualized by Coomassie brilliant blue R-250 (Sigma To generate virus, 293T cells were seeded in 6-well
Chemicals) staining, and cleaved HIV-2 Vpr was gel plates with 35-mm wells at a density of 4.5 1 105 cells
excised. The gel slice was mixed 1:1 with Freund’s per well the day prior to transfection. On the following
complete adjuvant and emulsified with an 18-gauge day, cells were transfected with 5 mg DNA per well by
needle prior to rabbit immunization. The rabbit was calcium phosphate precipitation. One day posttransfec-
boosted three subsequent times at 4-week intervals tion, cells were washed with PBS and reincubated with
with Vpr prepared in a similar manner except emulsifi- normal growth media. Two days posttransfection, cell
cation was performed in Freund’s incomplete adjuvant. supernatants were collected, clarified, and filtered
After the last boost, antisera could be diluted 1:2000 through a 0.2-mm membrane.
without any loss in linearity of response to 1 mg recom- Wild-type and mutant viruses were obtained from a
binant Vpr on the immunoblots demonstrating the Vpr- short term, productive infection of CEMx174 cells. Cells
antibody titers were in excess. Specificity was deter- were resuspended with virus inoculums at a concentra-
mined through immune detection of eukaryotically ex- tion of 1 1 106 cells/ml in the presence of 4 mg/ml
pressed HIV-2 Vpr whose detection could be blocked polybrene. Cells were infected at 377 for 4 hr, and then
by preadsorbing the antiserum with purified, recombi- cells were removed from inoculum, washed, and resus-
nant Vpr. Specificity was also determined by detection pended in RPMI medium supplemented with 10% FBS.
of Vpr in wild-type HIV-2 virion preparations compared After infection, cells were split 1:3 every 3 days. Every
to a negative control of virion stocks generated from alternate split, 1 1 107 uninfected, exponentially grow-
HIV-2 provirus with a vpr mutation. ing CEMx174 cells were added to the infected culture.
High titer rabbit antiserum directed against HIV-1 Vpr Fifteen and 18 days after infection, infected cell super-
were generated in a similar manner (W. C. Goh and M. natants were collected, clarified by low speed centrifu-
Emerman, unpublished data). Polyclonal rabbit peptide gation, and passed through 0.2-mm filters. Virus con-
antibodies directed toward HIV-2 Vpx have been pre- taining supernatants were layered over 20% sucrose
viously described (Guyader et al., 1989). Murine mono- cushions and centrifuged at 125,000 g for 2 hr at 47.
clonal antibody to HIV-2 p25 was obtained from the NIH Virion pellets were resuspended in standard buffer (100
AIDS Research and Reference Reagent Program. mM NaCl, 10 mM Tris – HCl, pH 7.4, 1 mM EDTA) and
stored at 0807 until analysis.
Immunoblots Electron microscope particle counts of virus stocks
were done as described (Alain et al., 1987; Kimpton andSDS–PAGE-resolved proteins were blotted onto Im-
Emerman, 1992). After fixing in gluteraldehyde and stain-mobilon-P (Millipore) and probed with either anti-VprHIV2 ing with 2% uranyl acetate, virus stocks were spiked with
sera diluted 1:1000, anti-VpxHIV2 sera diluted 1:2000, or a known concentration of 500-nm Latex beads. These
CAHIV2 monoclonal antibody diluted 1:2000. Secondary preparations were visualized with an electron micro-
antibodies were used at a dilution of 1:2000. Horse radish
scope, and negatively staining virions were counted rela-
peroxidase (HRP)-conjugated donkey immunoglobulin
tive to the beads to determine their concentration.
specific for rabbit immunoglobulins (Amersham) was
Pulse-chase and cell cycle analysisused to detect bound anti-VprHIV2 and anti-VpxHIV2 , and
goat anti-murine Ig conjugated to HRP (Cappel) was used One day posttransfection, 293T cells were washed,
starved for methionine and cysteine, and metabolicallyto detect the CAHIV2 monoclonal antibodies.
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1992), we began an analysis of functional similarities
between these proteins. Although it was known that
HIV-2 Vpx efficiently incorporates into the virion (Hen-
derson et al., 1988; Wu et al., 1994), the relative levels
of Vpr in HIV-2 particles had not been determined. To
examine these levels, we measured the relative virion
content of Vpr and Vpx of wild-type HIV-2ROD using puri-
fied recombinant Vpr and Vpx as standards for quantita-
tion (Fig. 1). Known amounts of purified recombinantFIG. 1. Coomassie blue staining of purified recombinant HIV-2 Vpr
standards were serially diluted and analyzed on immu-and Vpx. Protein preparations (2 mg each) were resolved on a 15%
SDS–polyacrylamide gel. Vpr is a 12–13 kilodalton (kDa) protein; noblots to compare to virion preparations (Fig. 2). Load-
whereas, Vpx is approximately 15 kDa. The Vpr preparation is contami- ings of virion stocks were manipulated to ensure that
nated by cleaved MBP. Densitometric analysis reveals the Vpr prepara- detectable amounts of the respective virion proteins
tion to be 50% pure and Vpx to be at least 95% pure. The Vpr doublet
were within the linear range of analysis of the recombi-present in the recombinant protein preparation appears to be the same
nant standards on the immunoblots. HIV-2ROD stocksdoublet present in virion preparations analyzed in immunoblots (e.g.,
see Fig. 2). Molecular weight sizing markers (in kDa) are shown. from newly infected CEMx174 stocks were used to ana-
lyze Vpr and Vpx content. Virus was collected soon
after infection to minimize selection and proliferation
labeled with [35S]methionine and cysteine, trans-label of variant virus populations. Cell-free virus was concen-
(ICN) at a concentration of 250 mCi/ml for 1 hr. After trated 100-fold by ultracentrifugation. The concentra-
labeling, cells were washed once with PBS and twice tion of HIV-2ROD Gag capsid antigen in the concentrated
with growth media and subsequently incubated in growth virus stock was measured using an ELISA for SIVmac
media. Cell lysates for protein analysis were subse- CA and found to contain the equivalent of 1.15 mg SIVmac
quently collected immediately, 1, 2, 4, 8, or 24 hr later. CA/ml culture prior to ultracentrifugation (Fig. 3C).
Cells were lysed at 47 in radioimmunoprecipitation assay
(RIPA) buffer (0.15 M NaCl, 0.01 M Tris–HCl, pH 7.4, 1%
Nonidet P-40 (NP-40), 1% sodium deoxycholate (DOC),
0.1% SDS) with a cocktail of protease inhibitors. After
lysis, the insoluble fraction was removed by centrifuga-
tion, and the soluble portion was frozen at0807. Proteins
of interest were immunoprecipitated, resolved by SDS –
PAGE, and quantitated by phosphorimage analysis (Mo-
lecular Dynamics).
For analysis of the cell cycle after transfection, we
adapted a previously described method (He et al., 1995;
Re et al., 1995). HeLa cells were plated at a density of 2
1 105 cells per 35-mm well of a 6-well plate. Each well
was transfected with either 5 mg of a Vpr or Vpx expres-
sion vector, 1.0 mg of a Tat expression construct, and 0.5
mg of a plasmid that conferred resistance to hygromycin
B (pCMVhph). Negative controls included (1) mock
transfected wells to ensure hygromycin sensitivity of tar-
get cells as well as (2) cells transfected with empty ex-
pression vector, pCMVTat, and pCMVhph. Triplicate
wells were transfected for each set of DNAs. One day
after transfection, medium was changed and 0.75 mg/ml
hygromycin B (Sigma) was added. Two days later, the FIG. 2. Examination of virion content of Vpx and Vpr in HIV-2ROD .
Immunoblots were probed after resolution of recombinant protein stan-cells were trypsinized and replated to remove dead cells,
dards and purified virion preparations on 15% SDS–polyacrylamideand 24 hr later, analyzed for cell cycle distribution as
gels and transfer to membranes. (A) Immunoaffinity purified polyclonaldescribed (Rogel et al., 1995).
rabbit serum to a Vpx peptide. Serial dilutions of recombinant Vpx
ranging from 1000 ng to 50 ng were compared to predetermined
amounts of HIV-2 as depicted in the panels. (B) Polyclonal rabbit serumRESULTS
to Vpr. Recombinant Vpr ranging from 500 to 25 ng compared relative
Vpr and Vpx content in virions to the virus stocks. In addition to wild-type HIV-2, HIV-2 mutated in vpx,
last lane, was analyzed for Vpr content. The amount of virion prepara-
Because of the amino acid similarities shared by Vpr tion used is represented in the panels as the volume of virus culture
it was derived from.of HIV-2 and HIV-1 and Vpx of HIV-2 (Tristem et al.,
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FIG. 3. Quantitation of virion content of Vpx and Vpr in HIV-2ROD . Band intensities of recombinant proteins (ordinate) were measured by densitometry
and values were used to plot a curve against the respective amounts of recombinant protein (abscissa). Film exposures displaying greatest linearity
within the range of analysis were used in quantitation (A, Vpx blot; B, Vpr blot). (C) Concentrations of proteins in the virus preparations. Concentrations
reflect relative amounts in unconcentrated cultures. HIV-2 CA quantitation was performed by enzyme linked immunoabsorbance assay for SIV core
antigen (Coulter). ND, not done.
The equivalent of 2.5 ml virus culture was used for lecular weights, Vpr is nearly 60-fold less abundant than
Vpx in particles.Vpr analysis of wild-type virions (Fig. 2B); whereas, the
To determine the average number of Vpr and Vpx mole-equivalent of 0.25 and 0.1 ml of HIV-2 culture was used
cules per virus particle, the amount of HIV-2ROD particlesfor Vpx analysis (Fig. 2A). Although the sensitivity of Vpr
in the virion preparation was enumerated by electrondetection was comparable to Vpx as indicated by the
microscopy (see Materials and Methods). The HIV-2RODrecombinant protein dilutions (Figs. 2A and 2B), virion
culture contained 2.87 1 1010 intact virus particles/mlVpr was difficult to detect in the immunoblots even after
prior to ultracentrifugation. Using the respective molecu-the use of 25-fold more virus culture than Vpx. Thus, the
lar weights of Vpx and Vpr, we converted the mass ofefficiency of Vpr incorporation into the HIV-2ROD particle
these proteins present in the virus preparation to theis substantially lower than Vpx.
number of molecules of each protein present in the prep-To more precisely quantify the relative amounts of Vpr
aration. One milliliter of the HIV-2ROD culture, therefore,and Vpx in the particle, densitometric analysis was per-
contains 6.83 1 1013 molecules Vpx and 1.21 1 1012formed on the film exposures, and dilutions of recombi-
molecules Vpr. This indicates that there are approxi-nant protein were used to generate a standard curve
mately 2400 Vpx and 40 Vpr proteins in the HIV-2ROD(Figs. 3A and 3B). Examining the Vpx content of wild-type
particle (Fig. 3C). The calculated number of Vpx mole-HIV-2ROD cultures indicated approximately 337 ng Vpx/
cules per particle resembles the estimated number of0.25 ml culture and 145 ng/0.1 ml culture (Fig. 2A, last
Gag molecules, 2000 to 4000 of each cleavage product,two lanes; Fig. 3A). This corresponds to an average Vpx
found in retrovirions (Davis and Rueckert, 1972; Strom-concentration of 1.40 mg/ml HIV-2ROD culture (Fig. 3C). berg et al., 1974).Vpr was not detectable in virions from this and other
Constraints on Vpr incorporation during HIV-2virion preparations unless the analyzed stock contained
replicationthe equivalent of several micrograms of SIVmac CA (e.g.,
Fig. 2B). Even then, only 23 ng Vpr/ml HIV-2ROD culture To determine why HIV-2ROD Vpr is present at a low
concentration in virion particles, several hypotheseswas detected (Fig. 3C). Adjusting for differences in mo-
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3C). Thus, provirally expressed Vpx does not limit virion
incorporation by Vpr.
The second hypothesis tested to explain the low
amount of HIV-2ROD Vpr present in particle was to ask
whether Vpr incorporation is saturated in HIV-2 because
of a low number of binding sites. Therefore, we assayed
the ability of Vpr to be incorporated when over-expressed
relative to the other virion genes (Fig. 4). If wild-type
virions are already saturated with Vpr, increased
amounts of Vpr during virion assembly should not influ-
ence virion levels of the protein. However, we found that
expression of Vpr in trans increases the amount of Vpr
present in particles relative to wild-type virions either in
the context of an intact provirus or in the context of a
gag/pro expression vector (Figs. 4A, compare lane 3 to
lane 1, and 4B). Therefore, HIV-2 particles do not have
FIG. 4. Incorporation of Vpr by trans-complementation. (A) Comple- a saturable threshold or physical constraint which acts
mentation of vpr mutant proviral constructs with vpr provided in trans, to limit Vpr incorporation during wild-type virus replica-
using pLTRVpr. Virus stocks were purified from culture supernatants tion. This suggests that Vpr levels in HIV-2 particles are
of transfected 293T cells. Immunoblots of the virus preparations were
regulated by the intracellular levels of Vpr in virus produc-analyzed using anti-Vpr sera, anti-Vpx sera, or anti-CA antibodies as
ing cells. In fact, virion particles generated from cotrans-labeled to the left of the blots. Lane 1, wild type HIV-2; lane 2, HIV-
2vpr alone; lane 3, HIV-2vpr with Vpr provided in trans. (B) Immunoblots fection of pLTRVpr with a minimal HIV-2 Gag expression
of Vpr incorporation into wild-type virus versus Vpr incorporation when construct, pHIV2GagPro, can contain up to 100-fold more
expressed in trans with HIV-2 Gag. Lane a, virus derived from 2.0 ml Vpr than wild-type virus obtained from infected cell cul-
culture of HIV-2 infected cells and is the same stock quantitated in Fig.
tures (Figs. 4B and 4C). Thus, virus generated during2; lane b, virus prepared from sucrose cushion concentrated culture
the course of infection never reaches the point of Vprsupernatants of 293T cells transfected with pCMVTat, pHIV2GagPro,
and pLTRVpr. Virus stocks were probed with either anti-HIV-2-CA saturation.
monoclonal antibody or anti-HIV-2-Vpr polyclonal serum as depicted
under the panels. (C) Vpr and CA content of the virion preparation Stability and function of Vpr
depicted in B. Densitometric analysis was performed on this virion
stock to determine Vpr concentration (blot not shown) and SIVmac ELISA These data suggested a third hypothesis to explain
was used to determine for CA concentration. Concentrations of Vpr the low levels of Vpr in the HIV-2 particle. We speculated
and CA reflect relative amounts in unconcentrated cultures.
that the intracellular concentration of Vpr may be lower
than Vpx in infected cells. This would limit the number
of Vpr molecules available for incorporation into virus
were tested. First, we examined whether HIV-2 Vpx had
during infection. Indeed, examination of steady-state lev-
an effect on Vpr incoporation. Because both HIV-1 Vpr
els of Vpr and Vpx in HIV-2-infected cells by Western
and HIV-2 Vpx require the C-terminus of their respective
immunoblots reveal Vpr to be near our detection level
Gag molecules for incorporation into particles (Kondo et
while intracellular levels of Vpx appear higher (Fig. 5).
al., 1995; Lu et al., 1993; Paxton et al., 1993; Wu et al.,
1994), it is possible that Vpx prevents Vpr incorporation
by occupying the same binding site in the assembling
virion. To determine whether Vpx competes with Vpr for
particle incorporation in vivo, HIV-2ROD virus stocks with
a proviral mutation in vpx, HIV-2vpx, were obtained from
infected CEMx174 cells. These viruses do not express
and, therefore, do not incorporate Vpx (Guyader et al.,
1989). After concentration, the equivalent of 1.25 ml of
this mutant virus culture was analyzed for Vpr content
(Fig. 3B, last lane). Densitometric measurements indicate
approximately 81 ng Vpr/1.25 ml mutant virus culture (Fig. FIG. 5. Steady-state levels of Vpr are low compared to Vpx. Immu-
3A), which is 0.065 mg/ml. The HIV-2 CA content of the noblots of Vpx and Vpr content of lysates from uninfected CEMx174
cells and cells infected with wild-type HIV-2. The equivalent of 1 1 105vpx-mutant virus preparation was measured by SIVmac
cells was loaded into each well of a 15% SDS–polyacrylamide gelELISA to CA to be 3.3 mg/ml culture. Normalizing the
before electrophoresis. After blotting, lysates were probed with either
mutant virus stock to the wild-type virus stock by CA, we polyclonal serum directed toward Vpx or Vpr as depicted in the panel.
measured the amount of Vpr in a wild-type particle to be ECL exposure time for the anti-Vpx blot was less than 20 sec, whereas
the anti-Vpr blot took 5 min.within 2% of the amount within HIV-2vpx particles (Fig.
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displays minimal deterioration over the course of the
pulse–chase experiment (Fig. 6A). The rate of Vpx turn-
over suggests a half-life of greater than 36 hr. Radiola-
beled HIV-1 Vpr is similarly robust, possessing cellular
half-life of about 20 hr. In contrast, the intracellular con-
centration of pulse-labeled HIV-2ROD Vpr decreases rap-
idly and possesses a cellular half-life of less than 90
min. Thus, the intracellular turnover of HIV-2ROD Vpr is
accelerated 13-fold relative to HIV-1 Vpr and 24-fold rela-
tive to HIV-2 Vpx. Because virion incorporation correlates
with steady-state levels of a protein within infected cells,
virion incorporation of HIV-2ROD Vpr appears to be self-
limiting.
Because the short half-life of HIV-2 Vpr limits its virion
incorporation, we next asked if the short half-life of HIV-
2 Vpr had an effect on an intracellular function. HIV-1
Vpr blocks cells from entering mitosis, causing them to
accumulate in G2 of the cell cycle (He et al., 1995; JowettFIG. 6. Correlation of half-life and cell cycle profile in transfected
et al., 1995; Re et al., 1995; Rogel et al., 1995). Therefore,cells. (A) The half-life of HIV-2ROD Vpr is short compared to Vpx and
HIV-1 Vpr. 293T cells were cotransfected with pCMVTat and either we asked if HIV-2 Vpr (and Vpx as a negative control),
pLAIvpr, pRODvpR, or pRODvpX, respectively. After metabolic labeling, similarly had an effect on the cell cycle by transiently
cells were chased with unlabeled media for 0, 1, 2, 4, 8, or 24 hr. Cells transfecting cells with expression plasmids for HIV-1 Vpr,
at various timepoints were lysed with RIPA buffer, and lysates were
HIV-2 Vpr, and HIV-2 Vpx. As expected, HIV-1 Vpr causedimmunoprecipitated with antibodies specific for HIV-2 Vpr, HIV-2 Vpx,
cells to accumulate in G2 of the cell cycle (Fig. 6B). Like-or HIV-1 Vpr. Immunoprecipitates were resolved by 15% SDS–PAGE.
After drying down, gels were exposed to phosphorimaging screens wise, as expected (He et al., 1995), Vpx had no effect on
to quantitate radioactive intensities of immunoprecipitated proteins. the cell cycle. On the other hand, we found that despite
Depicted autoradiographs were derived from 1 week exposures of the its short half-life, HIV-2 Vpr was able to affect the cell
gels to imaging film. Lanes are labeled to correspond to the time of
cycle profile of transfected cells (Fig. 6B). However, thethe chase in hours. (B) Representative cotransfection of HeLa cells with
effect of HIV-2 Vpr was attenuated relative to HIV-1 Vpr—pCMVTat, pCMVhph, and pLAIvpr, pRODvpR, or pRODvpX, respectively.
Hygromycin resistant cells were analyzed by flow cytometry for their the ratio of G1/G2 in cells transfected with HIV-1 Vpr
relative DNA contents (abscissa) by nuclear staining with propidium was 1:3.1, while the ratio of G1/G2 in cells transfected
iodide. The two peaks represent the number of cells possessing either with HIV-2 Vpr was 1:1.4 (the ratio of G1/G2 in cells
2 N or 4 N DNA content, corresponding to cells in either the G1 phase
transfected with HIV-2 Vpx was 1.5:1, the same as un-or G2 phase of the cell cycle, respectively. Cell numbers (ordinate)
transfected cells). These data indicate that HIV-1 Vpr andrepresent a relative linear distribution of at least 500 events in each
transfection set after gating. HIV-2 Vpr have similar functions in that both cause cells
to accumulate in G2 of the cell cycle. However, the effect
of HIV-2 Vpr is reduced relative to that of HIV-1 Vpr and
As before, the sensitivity of Vpr detection is comparable correlates with its increased protein turn-over. Thus, pro-
to Vpx in this assay (Fig. 2). Thus, low intracellular levels tein stability modulates both HIV-2 Vpr virion incorpora-
of Vpr correlate with its diminished presence in the virion. tion and function.
The steady-state levels of a protein are a function of
both the expression level of the protein as well as the DISCUSSION
rate at which the protein turns over within the cell. Immu-
noprecipitation after pulse-labeling infected cells indi- Vpr is incorporated into the HIV-2ROD particle at levels
cates efficient proviral expression of HIV-2ROD Vpr and significantly less than Vpx. While Vpx is approximately
Vpx (data not shown). Therefore, to examine the stability equimolar to virion structural proteins, Vpr appears in
of HIV-2ROD Vpr relative to Vpx and HIV-1LAI Vpr, 293T particles at levels close to the viral enzymatic proteins,
cells were transfected with expression vectors encoding such as RT. We find that Vpx does not compete with Vpr
these respective genes for pulse–chase analyses. These for incorporation. Rather low virion levels of Vpr corre-
proteins were examined for stability in the absence of spond to diminished levels of Vpr within HIV-2ROD-in-
proviral gag expression to eliminate the confounding is- fected cells; although increased virion incorporation of
sue of protein export due to virion secretion. Vpr can be achieved artificially through cotransfection of
The day after transfection, cells were radiolabeled for vpr expression vectors with HIV-2 proviral constructs.
1 hr, after which they were washed free of radioactive These data indicate that the cellular steady-state levels
media and continued in culture with normal growth me- of HIV-2ROD Vpr are critical for efficient virion incorpora-
tion. Examination of the intracellular half-life of HIV-2RODdia for various time periods. HIV-2 Vpx is very stable and
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Vpr reveals an accelerated turnover of the protein com- phage infection, and HIV-2ROD Vpr, which perturbs cell
division control despite inefficiently incorporating into vi-pared to HIV-1 Vpr or HIV-2 Vpx. Moreover, we find that
HIV-2 Vpr, like HIV-1 Vpr, causes cells to accumulate in rions.
In vivo studies with SIV mutated in vpr have failedG2 of the cell cycle, but the effect is attenuated. There-
fore, protein stability is a major determinant of both virion to demonstrate a role of the protein in pathogenesis.
However, if HIV-2/SIVsmm/mac vpr and vpx have arisen fromincorporation and function of HIV-2 Vpr.
The low amounts of HIV-2 Vpr in the virion particle the duplication of a prototype gene which closely resem-
bles HIV-1 vpr, it is reasonable to assume that theseand its rapid rate of intracellular turnover is relatively
unexpected. Other studies seem to indicate that Vpr from independent genes performing separate functions are
more efficient than one gene performing the same twothe closely related SIVmac isolate appears to more effi-
ciently incorporate into particles (Gibbs et al., 1995; Yu functions. Conversely, HIV-1 Vpr function may then be
regarded as an imperfect composite of HIV-2 Vpr andet al., 1990), although those studies did not quantify with
standards as we have done here, and are therefore not Vpx functions. If so, HIV-2/SIV deficient in either vpr or vpx
would not be functionally equivalent to HIV-1 defective indirectly comparable. Until further quantitative studies are
done, we cannot yet distinguish whether the diminished vpr, and HIV-2/SIV deficient in both vpr and vpx would
be more debilitated than HIV-1 mutated in vpr. Thus,virion incorporation of HIV-2ROD Vpr is representative of
the differences between HIV-2 and SIV isolates or re- studies using primates as a model for immunodeficiency
virus infection could underestimate the role of vpr in hu-flects selection of particular vpr allele in cell culture.
Experimental data suggest HIV-2 Vpx is functionally man disease.
analogous to HIV-1 Vpr in several respects. Both pro-
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